SOTIO to Present New Preclinical Data on IL-15 Superagonist, SO-C101, at the 2020 AACR Virtual Annual Meeting II

June 15, 2020 Source: Press Release SOTIO, a clinical stage immuno-oncology company and Cytune Pharma, both owned by PPF Group, announced that they will present new preclinical data on SO-C101, an IL-15 superagonist currently being studied in a Phase 1 trial for the treatment of advanced solid tumors, in a virtual poster presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II being held from June 22-24, 2020. Poster presentation details Poster title: SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8 + T cells dependent manner Abstract: 6686 / 2 Session: Session PO.IM02.20 - Immunomodulatory Agents and Interventions 3 Date/Time: Monday, June 22, 2020, 9:00 a.m. – 6:00 p.m. EDT A copy of the presentation materials can be accessed on the SOTIO website once the presentation concludes. Cytune Pharma is responsible for the clinical development of SO-C101, SOTIO is sponsor of the Phase 1 clinical trial.

The release as fetched from its publisher. sotio.com ↗